Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innate Pharma S.A. ADR
(NQ:
IPHA
)
2.210
-0.050 (-2.21%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Innate Pharma S.A. ADR
< Previous
1
2
3
4
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
June 10, 2024
Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
March 11, 2024
Via
Benzinga
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 05, 2023
Via
Benzinga
Regulatory Hurdle For Innate Pharma's Blood Cancer Studies
October 05, 2023
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201...
Via
Benzinga
Exposures
Product Safety
Why Shares of Innate Pharma Jumped Thursday
June 08, 2023
The company's collaboration agreement with Sanofi could soon pay off.
Via
The Motley Fool
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 03, 2023
Via
Benzinga
Earnings Scheduled For March 23, 2023
March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
Via
Benzinga
US Stocks Open Lower; Nasdaq Slides Over 100 Points
December 27, 2022
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 27, 2022
Via
Benzinga
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
December 27, 2022
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 19, 2022
Via
Benzinga
After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs
December 19, 2022
Via
Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket
December 19, 2022
Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM ImmunoTech recently reported safety, tolerability and biological activity data for intranasal ampligen in...
Via
Benzinga
Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer
December 12, 2022
Via
Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
September 20, 2022
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.
Via
Benzinga
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session
September 19, 2022
Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 19, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
September 19, 2022
We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news behind them!
Via
InvestorPlace
Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket
September 19, 2022
Gainers FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday.
Via
Benzinga
Earnings Scheduled For September 15, 2022
September 15, 2022
Companies Reporting Before The Bell • Boqii Holding (NYSE:BQ) is estimated to report earnings for its first quarter.
Via
Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
August 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
August 02, 2022
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.
Via
Benzinga
This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday's Mid-Day Session
August 01, 2022
Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022.
Via
Benzinga
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
August 01, 2022
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.